Skip to main content
Signal8
Smith Robert Joseph profile photo

Robert Joseph Smith

CIK: 0002008764

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CITIUS ONCOLOGY, INC. logo
CTOR

CITIUS ONCOLOGY, INC.

Director
Citius Pharmaceuticals, Inc. logo
CTXR

Citius Pharmaceuticals, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • CITIUS ONCOLOGY, INC. logo
    CTOR

    CITIUS ONCOLOGY, INC.

    Sep 19, 2025
    Award(A)
    Direct
    300K shares-
  • CITIUS ONCOLOGY, INC. logo
    CTOR

    CITIUS ONCOLOGY, INC.

    Dec 12, 2024
    Award(A)

    Stock Option (Right to Buy)

    Direct
    125K shares-
  • Citius Pharmaceuticals, Inc. logo
    CTXR

    Citius Pharmaceuticals, Inc.

    Nov 7, 2024
    Award(A)

    Stock Option (Right to Purchase Common Stock)

    Direct
    125K shares-

1-3 of 3

About Smith Robert Joseph

Smith Robert Joseph (SEC CIK 0002008764) files insider reports with the SEC as Director of CITIUS ONCOLOGY, INC. (CTOR) and Director of Citius Pharmaceuticals, Inc. (CTXR).

Signal8 holds 5 ownership filings by Smith Robert Joseph, all Form 4s, filed between Nov 12, 2024 and Dec 22, 2025. Those filings report 3 transactions, from Nov 7, 2024 to Sep 19, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Smith Robert Joseph's filings is in CRANFORD, NJ.

Recent filings by Smith Robert Joseph

  • Sep 19, 2025: Grant or award of CTOR shares (Form 4, code A).
  • Dec 12, 2024: Grant or award of CTOR derivative securities (Form 4, code A).
  • Nov 7, 2024: Grant or award of CTXR derivative securities (Form 4, code A).

Other insiders filing for CITIUS ONCOLOGY, INC. (CTOR)

How to read Form 4 transaction codes